Sintilimab plus bevacizumab shows therapeutic potential in ovarian clear cell carcinoma

In the treatment of patients with relapsed or persistent ovarian clear cell carcinoma, the combination of sintilimab plus bevacizumab has demonstrated promising antitumour activity and manageable safety in the phase II INOVA trial.

INOVA included adults with histologically confirmed relapsed or persistent ovarian clear cell carcinoma, had an Eastern Cooperative Oncology Group performance status score of 0–2, and previous exposure to at least one cycle of platinum-containing chemotherapy. These patients were randomly assigned to receive sintilimab 200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression.

The primary endpoint was objective response rate, as assessed by independent central review based on Response Evaluation Criteria in Solid Tumours version 1.1. A total of 41 patients received at least one dose of sintilimab in combination with bevacizumab, and 37 completed response evaluation.

Over a median follow-up of 16.9 months, 15 patients had an objective response with the combination therapy, for an objective response rate of 40.5 percent (95 percent confidence interval [CI], 24.8–57.9). Of these patients, five (14 percent) showed complete response and 10 (27 percent) showed partial response.

Grade 3 treatment-emergent adverse events (TEAEs) occurred in three patients (7 percent), including proteinuria in one, myocarditis in another, and rash in the third. None of the patients had TEAEs of worse than grade 3 severity.

Two patients had serious TEAEs (5 percent), including one patient with immune-related myocarditis and another with hypertension and renal dysfunction. No cases of treatment-related deaths were recorded.